CorMedix
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
300 Connell Dr Ste 4200, Berkeley Height...Phone Number
(908) 517-9500Website
www.cormedix.comRevenue
$311.7 MillionStock Symbol
CRMDIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
1
1
1
1
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Explore more
CorMedix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CorMedix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if CorMedix has recently received funding, and reach out quickly before it becomes old news!
CorMedix, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at CorMedix
Click to see if CorMedix had a recent Job posting/layoffs
Earning: See what the market has to say on CorMedix recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once CorMedix has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when CorMedix launches new products
Check out if CorMedix is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to CorMedix
Compare insights from companies similar to CorMedix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CorMedix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CorMedix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CorMedix.
CorMedix financials insights
Gather financial insights about CorMedix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Stock Offering
$12.5M
CorMedix Tech Stack
A closer look at the technologies used by CorMedix
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
CorMedix has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Pain Point
faces uncertainty regarding the timing of potential TDAPA legislation, which likely needs to be attached to another piece of legislation. The company cannot speculate on whether this can happen before June 30 or December 31, 2026, but believes there is a pathway for potential retroactivity of some aspects of the bill to impact positively on DefenCath if it happens after June 30.
Governmental Affairs & Regulation, Regulations
Project
Contracts
CorMedix News & Media
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fireside chat is as follows:CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q1 2026 Earnings Call May 14, 2026 8:30 AM EDTCompany ParticipantsJoseph Todisco - CEO & Chairman of the Board of...Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
‒ Q1 2026 Net Revenue of $127.4 million ‒CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 14, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CorMedix
Sign Up For FreeTo access detailed company insights
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections... Read More
